

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, a clinical organisation commented that:

- a) CAR T-cell therapy will only be delivered in specialised centres. This may mean longer travelling distances for some people.
- b) Consideration should be given to young adults aged between 16 to 17 years who were not enrolled in clinical trials for axicabtagene ciloleucel but are treated similarly to people aged 18 years in UK CAR T-cell therapy centres.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

NICE is required by law to look at any protected characteristics and whether any recommendation could cause unlawful discrimination.

- a) Where similar issues have been raised in previous appraisals (e.g. TA559 and TA567), the commissioning expert from NHS England confirmed that national multidisciplinary teams would be established to ensure equality of referral and treatment access.
- b) The committee will not make recommendations based on age but will usually be restricted by the marketing authorisation for axicabtagene

autoleucel.

The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Ross Dent

Date: 10 December 2021